Zobrazeno 1 - 10
of 1 002
pro vyhledávání: '"tumor shrinkage"'
Autor:
Yuchen Zhou, Zhonghan Wu, Haowen Wang, Ke Zhang, Hua Chen, Siyu Zhu, Andriamifahimanjaka Sitrakiniaina, Yanting Wu, Shaopeng Yang, Xiaobo Sun, Wenfeng Li, Xiaoming Lin, Jingjing Jin
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-14 (2024)
Abstract Background Small-cell lung cancer (SCLC) is a leading cause of cancer-related death. However, the prognostic value of the tumor shrinkage rate (TSR) after chemotherapy for SCLC is still unknown. Methods We performed a retrospective analysis
Externí odkaz:
https://doaj.org/article/2490c664855f4f738a9076ec50c3d1c0
Autor:
K. Shimozaki, K. Fukuda, A. Ooki, I. Nakayama, K. Yoshino, M. Tamba, S. Udagawa, S. Fukuoka, H. Osumi, T. Wakatsuki, D. Takahari, E. Shinozaki, M. Ogura, K. Chin, K. Yamaguchi
Publikováno v:
ESMO Gastrointestinal Oncology, Vol 5, Iss , Pp 100072- (2024)
Background: This study aimed to evaluate the safety and efficacy of first-line nivolumab plus chemotherapy for real-world patients with human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (AGC). Materials and methods: Thi
Externí odkaz:
https://doaj.org/article/4ccb1cc6e20a47ef9fef2ed854e26a99
Autor:
Mengfan Wang, Siyao Du, Si Gao, Ruimeng Zhao, Shasha Liu, Wenhong Jiang, Can Peng, Ruimei Chai, Lina Zhang
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-15 (2024)
Abstract Background MRI-based tumor shrinkage patterns (TSP) after neoadjuvant therapy (NAT) have been associated with pathological response. However, the understanding of TSP after early NAT remains limited. We aimed to analyze the relationship betw
Externí odkaz:
https://doaj.org/article/9f3e996cab2a41d79937a61e8d9f5bbf
Autor:
Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D. Danenberg, Narikazu Boku, Takako Eguchi Nakajima
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Background Long‐term anti‐EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single‐arm, phase II trial aimed to investigate the strategy of switching from cetuximab to bevacizumab in combination with FO
Externí odkaz:
https://doaj.org/article/f1dd28fe734a4a8888bd792971f6399b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Akira Ooki, Satoshi Morita, Akihito Tsuji, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Masahiko Ando, Junichi Sakamoto, Kensei Yamaguchi
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Purpose Although early tumor shrinkage (ETS) is a predictor of improved overall survival (OS), the association between ETS and health-related quality of life (HRQOL) remains unclear for patients with metastatic colorectal cancer (mCRC) treat
Externí odkaz:
https://doaj.org/article/8e277a2749b9411aa5325e80e6e2203a
Autor:
Congxiao Wang, Chao Liu, Jun Chen, Han Jiang, Wei Zhang, Lili Yang, Xueda Li, Zixiang Li, Lijing Peng, Xiaokun Hu, Peng Sun
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background A more extensive surgical resection of glioma contributes to improved overall survival (OS) and progression-free survival (PFS). However, some patients miss the chance of surgical resection when the tumor involves critical structu
Externí odkaz:
https://doaj.org/article/6b1a01a6383f49adbff3938200f5d009
Autor:
Masaki Ishida, MD, Kenji Morimoto, MD, PhD, Tadaaki Yamada, MD, PhD, Takayuki Takeda, MD, PhD, Shinsuke Shiotsu, MD, PhD, Koji Date, MD, Taishi Harada, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Yoshizumi Takemura, MD, PhD, Takahiro Yamada, MD, PhD, Hibiki Kanda, MD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100493- (2023)
Introduction: In recent years, programmed cell death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy was found to have favorable clinical outcomes in patients with extensive-stage SCLC (ES-SCLC). The usefulness of early tumor shrinkag
Externí odkaz:
https://doaj.org/article/8ad42c2ad9154398a211e05aa540b2ca
Autor:
Osman Öcal, Regina Schinner, Kerstin Schütte, Enrico N. de Toni, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Bernhard Gebauer, Christoph J. Zech, Christian Sengel, Irene Bargellini, Antonio Gasbarrini, Bruno Sangro, Maciej Pech, Peter Malfertheiner, Jens Ricke, Max Seidensticker, for the SORAMIC study group
Publikováno v:
Cancer Imaging, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background The aim of this study was to explore the relationship between follow-up imaging characteristics and overall survival (OS) in advanced hepatocellular carcinoma (HCC) patients under sorafenib treatment. Methods Associations between
Externí odkaz:
https://doaj.org/article/971541f80cc14c379bd9083efd0fc4b4
Autor:
Abel Cordoba, Benedicte Durand, Alexandre Escande, Sophie Taieb, Mariem Ben Haj Amor, Marie Cecile Le Deley, Andree Michel, Florence Le Tinier, Delphine Hudry, Carlos Martinez, Eric Leblanc, Stephanie Becourt, Cyril Abdedaim, Lucie Bresson, Eric Lartigau, Xavier Mirabel, Fabrice Narducci
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectivePelvic magnetic resonance imaging (MRI) is a key exam used for the initial assessment of loco-regional involvement of cervical cancer. In patients with locally advanced cervical cancer, MRI is used to evaluate the early response to radiochem
Externí odkaz:
https://doaj.org/article/3807379e9b244d51a91c9546c51d87f2